Lifecore outlines $74M-$76M revenue target for transition period while advancing commercial wins and margin expansion
Source: SeekingAlpha
2025-11-06 20:56:46 ET
More on Lifecore Biomedical
- Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript
- Lifecore Biomedical, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Lifecore Biomedical: Our Fill-Finish CDMO
- Lifecore Biomedical GAAP EPS of -$0.29 beats by $0.01, revenue of $31.1M beats by $4.63M
- Lifecore granted Sector Weight rating at KeyBanc on growth trajectory
Read the full article on Seeking Alpha
For further details see:
Lifecore outlines $74M–$76M revenue target for transition period while advancing commercial wins and margin expansion
Lifecore Biomedical Inc.
NASDAQ: LFCR
LFCR Trading
-2.47% G/L:
$6.92 Last:
36,764 Volume:
$6.82 Open:
LFCR Latest News
March 10, 2026 04:05:00 pm
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
March 09, 2026 04:05:00 pm
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
LFCR Stock Data
$276,501,678
20,569,027
4.87%
36
N/A
Biotechnology & Life Sciences
Healthcare
US
Chaska
